Respiratory Viral Multiplex PCR and SARS-CoV-2 PCR Data: All Age Groups
Percentage of Specimens Positive
December 2023:
- Rhino/Enterovirus: 24.6%
- Rhinovirus: 16.7%
- SARS-CoV-2: 7.9%
- RSV: 1.6%
- Parainfluenza 1-4: 8.1%
- Human metapneumovirus: 7.5%
- Coronavirus (non-SARS-CoV-2): 1.8%
- Influenza A: 7.6%
- Influenza B: 1.8%
- Adenovirus: 5.1%
- Bordetella pertussis: 1.3%
- Bordetella parapertussis: 1.4%
January 2024:
- Rhino/Enterovirus: 24.3%
- Rhinovirus: 21.2%
- SARS-CoV-2: 8.8%
- RSV: 2.2%
- Parainfluenza 1-4: 5.3%
- Human metapneumovirus: 3.0%
- Coronavirus (non-SARS-CoV-2): 1.1%
- Influenza A: 2.7%
- Influenza B: 5.5%
- Adenovirus: 3.0%
- Bordetella pertussis: 1.0%
- Bordetella parapertussis: 3.4%
Epidemiological Weeks 1 - 5:
- SARS-CoV-2: Stable positivity rates across weeks.
- Influenza A & B: Remain low at approximately 3.5% positivity each.
- RSV: Increased from 1.2% (week 1) to 3.4% (week 5).
Atypical Bacterial Pathogens (Weeks 1 - 5):
Weekly Cases Detected:
Bordetella pertussis:
- Weeks 1–5: 5, 9, 7, 6, 9
Mycoplasma pneumoniae:
- Weeks 1–5: 5, 15, 13, 23, 10
Chlamydia pneumoniae:
- Weeks 1–5: 5, 7, 10, 8, 18
Legionella pneumophila:
- No cases detected.
Age Distribution of Atypical Bacterial Pathogens:
Bordetella pertussis:
- 0–6 months: 22%
- 6–12 months: 6%
- 1–5 years: 36%
- 6–12 years: 11%
- 13–18 years: 0%
- 19–64 years: 22%
65 years: 6%
Mycoplasma pneumoniae:
- 0–6 months: 0%
- 6–12 months: 8%
- 1–5 years: 27%
- 6–12 years: 27%
- 13–18 years: 8%
- 19–64 years: 24%
65 years: 6%
Chlamydia pneumoniae:
- 0–6 months: 2%
- 6–12 months: 4%
- 1–5 years: 44%
- 6–12 years: 31%
- 13–18 years: 11%
- 19–64 years: 15%
65 years: 0%
Paediatric Respiratory Viral Multiplex PCR Data (0 – 12 years):
<1 year Age Group - Specimen Positivity:
December 2023:
- Rhino/Enterovirus: 36.2%
- Rhinovirus: 25.5%
- Parainfluenza 1-4: 11.8%
- Adenovirus: 5.8%
- RSV: 4.0%
- Influenza A: 11.7%
- Influenza B: 4.2%
- SARS-CoV-2: 6.8%
January 2024:
- Rhino/Enterovirus: 35.1%
- Rhinovirus: 27.4%
- Parainfluenza 1-4: 8.8%
- Adenovirus: 5.3%
- RSV: 5.8%
- Influenza A: 4.2%
- Influenza B: 4.2%
- SARS-CoV-2: 8.6%
1 - 5 year Age Group - Specimen Positivity:
December 2023:
- Rhino/Enterovirus: 43.6%
- Rhinovirus: 28.2%
- Parainfluenza 1-4: 14.6%
- Adenovirus: 15.3%
- RSV: 3.0%
- Influenza A: 15.6%
- Influenza B: 4.1%
- SARS-CoV-2: 4.3%
January 2024:
- Rhino/Enterovirus: 44.3%
- Rhinovirus: 37.5%
- Parainfluenza 1-4: 9.7%
- Adenovirus: 11.7%
- RSV: 4.6%
- Influenza A: 3.8%
- Influenza B: 4.6%
- SARS-CoV-2: 5.9%
6 - 12 year Age Group - Specimen Positivity:
December 2023:
- Rhino/Enterovirus: 29.0%
- Rhinovirus: 13.3%
- Parainfluenza 1-4: 6.7%
- Adenovirus: 12.9%
- RSV: 0.6%
- Influenza A: 7.1%
- Influenza B: 0.0%
- SARS-CoV-2: 2.6%
January 2024:
- Rhino/Enterovirus: 33.5%
- Rhinovirus: 31.3%
- Parainfluenza 1-4: 3.1%
- Adenovirus: 7.8%
- RSV: 0.6%
- Influenza A: 3.6%
- Influenza B: 1.4%
- SARS-CoV-2: 3.9%
Additional Comments:
- Most frequently detected viruses in January 2024 per age group:
- <1 year: Rhino/Enterovirus, Rhinovirus, Parainfluenza 1-4, SARS-CoV-2.
- 1 - 5 years: Rhino/Enterovirus, Rhinovirus, Adenovirus, Parainfluenza 1-4.
- 6 - 12 years: Rhino/Enterovirus, Rhinovirus, Adenovirus.
Continue Reading